AstraZeneca strategy on track to deliver sustainable growth and value through innovation
AstraZeneca will today provide an update for institutional investors and financial analysts on the progress against the company’s strategic priorities of achieving scientific leadership and returning to growth
Access support at the Business Improvement Hub
CB1 Associates invites you to become a part of the Business Improvement Hub meeting at Homerton College on 8th December.
Race is on to deliver autonomous vehicles
Industry experts are lining up at Silverstone Park for a Cambridge Wireless conference to debate technical, commercial and regulatory challenges.
Caroline Flint visits Cambridge
Caroline Flint MP, Shadow Secretary of State for Department of Energy and Climate Change, is to visit Cambridge Cleantech this week and hold a roundtable with its members.
Interested in salivary Cortisol research? Here are examples concerning 'work stress'
Psychologists are using the minimally invasive salivary Cortisol assays more and more to quantify the results of their stress research.
Global Regulatory Services shortlisted for TOPRA Awards for regulatory excellence
Greer Deal, Director of Global Regulatory Services (GRS), is delighted to be shortlisted for the TOPRA Futures Award especially because the Award is so relevant to GRS and the company strap line "driving innovation to market success". Winners will be announced at the TOPRA Awards Gala Dinner in London on Tuesday 9 December 2014.
Artificial muscle capable of ‘remembering’ movements developed
Researchers from the University of Cambridge have developed artificial muscles which can learn and recall specific movements, the first time that motion control and memory have been combined in a synthetic material.
Guinevere’s debut novel is snapped up
Anglia Ruskin University graduate Guinevere Glasfurd is celebrating after her debut novel was snapped up by publishers Two Roads, an imprint of John Murray Press.
Arkwright ceremonies 2014 – TWI supports future leaders in engineering
The Arkwright Scholarships Trust recently made its largest ever award of scholarships to future leaders in the engineering profession. Sixth form scholarships were awarded to 410 young people at ceremonies in London and Glasgow.
Dr Chris Lennard steps up to CSC Board of Trustees
The Cambridge Science Centre (CSC) is preparing for a phase of expansion based on the success of its first 18 months of operations.
Only two weeks to go till the Winter Cambridge Literary Festival
With just two weeks to go until the Cambridge Literary Festival winter outing, tickets are selling fast.
Overuse of antibiotics for acne; the hidden resistance threat
Light therapy is a promising alternative to antibiotics in the treatment of acne.
Babraham Institute launches new website
Today we’ve unveiled our new website offering dynamic and responsive ways to explore the Institute’s research, staff, opportunities and activities.
J A Kemp & CPA Global sign new long-term contract for renewals and IP support services
J A Kemp has entered into a new ten-year strategic agreement with intellectual property (IP) management services and software provider CPA Global, building on the long-standing successful relationship between the two firms.
Growing 3D lung tissue in the lab to beat cancer
Help two University of Cambridge doctors build real lung tissue using stem cells to uncover more about the biggest cancer killer.
Chain Reaction is just days away
The Chain Reaction is back for its fourth year, bigger and better than ever. At this spectacular Cambridge Science Centre event at the Guildhall on Saturday (22 November), families, schools and local companies will get stuck into building a huge chain of crazy contraptions that trigger one another around the room and across the stage.
Do you have the 2% mindset?
Do you have the 2% mindset? Where in your career or your life are you choosing to take the safe option instead of doing what you'd most like, because fear is getting in the way, asks Hilary Jeanes of PurpleLine Consulting.
Horizon Discovery Group signs agreement with top pharma company for approximately $750,000
Horizon Discovery Group plc, a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced that its Horizon CombinatoRx division has been contracted by a top ten pharma company to profile a lead oncology asset. Under the terms of the agreement, Horizon CombinatoRx will be paid approximately USD $750,000 (GBP £469,000) for…
Ferret genome study provides clues to how the respiratory system responds
In what is likely to be a major step forward in the study of influenza, cystic fibrosis and other human disease, an international research effort has sequenced the ferret genome and used the sequence to analyse how influenza and cystic fibrosis affects respiratory tissues at the cellular level.
Johnson Matthey wins corporate reporting award
Johnson Matthey has been awarded ‘Best Sustainability and Stakeholder Disclosure in the FTSE 100’ by the Institute of Chartered Secretaries and Administrators.
First FinTech Weekend to challenge the big bank theory
Accelerate Cambridge, Cambridge Judge Business School’s in-house start-up “accelerator”, is hosting the first ever Cambridge FinTech Startup Weekend next weekend (21-23 November).
Construction begins on the University of Cambridge Primary School
Construction of the University of Cambridge Primary School began last week, marked by a groundbreaking ceremony with the Vice-Chancellor, Professor Sir Leszek Borysiewicz, as guest of honour.
MedImmune presents promising new data in systemic lupus
MedImmune, the global biologics research and development arm of AstraZeneca, today announced it will be presenting positive data from a Phase IIb study on sifalimumab, a novel monoclonal antibody targeting interferon being investigated for treatment in patients with moderate to severe systemic lupus erythematosus (SLE or lupus), at the American College of Rheumatology (ACR) 2014 Annual Meeting in…
MedImmune presents positive Phase IIB data for rheumatoid arthritis treatment
MedImmune, the global biologics research and development arm of AstraZeneca, today announced positive results from a Phase IIb study of mavrilimumab, a first-in-class investigational monoclonal antibody for the treatment of rheumatoid arthritis (RA). Study results are being presented in several abstracts at the American College of Rheumatology (ACR) 2014 Annual Meeting taking place in Boston, MA.
Putting your business in the frame
They say a picture’s worth a thousand words – and in marketing, it’s often more. With the use of smartphones at an all-time global high, capturing the moment has never been easier: and it’s never been more vital. But as with all things that are used to promote your business, please handle with extreme caution, warns Spirus.